Cheng Kenneth T.
National Center for Biotechnology Information, NLM, NIH, Bethesda, MD,
1-([4-methoxy-C]-3,4-Dimethoxyphenethyl)-4-[3-(4-fluorophenyl)propyl]piperazine ([C]SA5845) is a radioligand developed for positron emission tomography (PET) imaging of the sigma (σ) receptors. [C]SA5845 is a potent σ receptor agonist labeled with C, a positron emitter with a physical half-life () of 20.4 min (1). σ receptors are functional, membrane-bound proteins distributed in the central nervous system (CNS) and peripheral organs such as the gastrointestinal tract and immune systems (2). The CNS σ receptors are unique binding sites related to higher brain functions (3). They are distinct from opiate and phencyclidine binding sites. There are at least two subtypes of σ receptors σ and σ receptors. The precise mechanism of the functional response of these receptors is not entirely known. These receptors appear to be involved in numerous pharmacological and physiologic functions, and they also modulate a number of central neurotransmitter systems, including noradrenergic, glutamatergic, and dopaminergic systems. phencyclidine and derivatives, cocaine and derivatives, some neuroleptics, atypical antipsychotic agents, and other chemically unrelated compounds can bind to the σ receptor sites. Studies have shown that these receptors may play a role in pathogenesis of psychiatric disorders (4, 5). These receptors are also expressed on a number of human and murine tumors (6). The σ receptor subtypes have a molecular weight of ≈25 kDa, and through the process of cloning they have shown a 30% sequence homology with the yeast C89-C7 sterol isomerase (2, 7, 8) The σ receptor subtypes have a molecular weight of ≈21.5 kDa and have not been cloned. The σ receptors are thought to be involved in certain neuropsychiatric disorders, and the σ receptors are also implicated in malignant neoplastic diseases. Because of these effects, σ receptor ligands may be useful for detection and treatment in neurology and oncology. Matsuno et al. (9) developed a potent σ agonist, 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)-piperazine dihydrochloride (SA4503), which is highly selective for σ receptors versus σ receptors. Small modifications in the SA4503 structure appear to have profound effects on the σ/σ receptor affinity and selectivity (10). Fujimura et al. (11) prepared its fluorinated analog, SA5845, and reported that this compound had a high affinity for σ receptors. Kawamura et al. (12, 13) radiolabeled SA5845 with C and evaluated its potential for PET studies of σ receptors in CNS and tumors.
1-([4-甲氧基-C]-3,4-二甲氧基苯乙胺)-4-[3-(4-氟苯基)丙基]哌嗪([C]SA5845)是一种开发用于西格玛(σ)受体正电子发射断层扫描(PET)成像的放射性配体。[C]SA5845是一种用C标记的强效σ受体激动剂,C是一种物理半衰期为20.4分钟的正电子发射体(1)。σ受体是分布于中枢神经系统(CNS)以及胃肠道和免疫系统等外周器官中的功能性膜结合蛋白(2)。中枢神经系统的σ受体是与高级脑功能相关的独特结合位点(3)。它们与阿片类和苯环己哌啶结合位点不同。σ受体至少有两种亚型,即σ1和σ2受体。这些受体功能反应的确切机制尚不完全清楚。这些受体似乎参与了众多药理和生理功能,并且它们还调节包括去甲肾上腺素能、谷氨酸能和多巴胺能系统在内的多种中枢神经递质系统。苯环己哌啶及其衍生物、可卡因及其衍生物、一些抗精神病药物、非典型抗精神病药物以及其他化学结构不相关的化合物均可与σ受体位点结合。研究表明,这些受体可能在精神疾病的发病机制中起作用(4,5)。这些受体也在多种人类和小鼠肿瘤中表达(6)。σ1受体亚型的分子量约为25 kDa,通过克隆过程显示与酵母C89-C7甾醇异构酶有30%的序列同源性(2,7,8)。σ2受体亚型的分子量约为21.5 kDa,尚未克隆。σ1受体被认为与某些神经精神疾病有关,而σ2受体也与恶性肿瘤疾病有关。由于这些作用,σ受体配体可能在神经病学和肿瘤学的检测和治疗中有用。松野等人(9)开发了一种强效σ激动剂,1-(3,4-二甲氧基苯乙胺)-4-(3-苯基丙基)-哌嗪二盐酸盐(SA4503),它对σ1受体相对于σ2受体具有高度选择性。SA4503结构上的微小修饰似乎对σ1/σ-2受体亲和力和选择性有深远影响(10)。藤村等人(11)制备了其氟化类似物SA5845,并报道该化合物对σ1受体具有高亲和力。川村等人(12,13)用C对SA5845进行放射性标记,并评估了其在中枢神经系统和肿瘤中进行σ受体PET研究的潜力。